Tamoxifen in patients with advanced pancreatic adenocarcinoma (Review)

Oncology Reports

Volumn 3, Issue 1, 1996, Pages 17-19

  Mikulski, Stanislaw M ^a  

^a Alfacell Corporation   (United States)

Author keywords

endocrine factors; Onconase ; pancreactic cancer; survival

Indexed keywords

CYPROTERONE ACETATE; RANPIRNASE; TAMOXIFEN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW;

EID: 0030065632     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (2)

1. Greenway BA: Carcinoma of the exocrine pancreas: A sex hormone responsive tumor? Br J Surg 74: 441-442, 1987.
2. Upp JR Jr, Olson D, Poston GJ, Alexander RW, Townsend CM Jr and Thompson JC: Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201-995. Am J Surg 155: 29-35, 1988.